Compare CC & NBTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CC | NBTX |
|---|---|---|
| Founded | 2014 | 2003 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.0B |
| IPO Year | 2014 | 2018 |
| Metric | CC | NBTX |
|---|---|---|
| Price | $14.46 | $33.41 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 1 |
| Target Price | $20.11 | ★ $36.00 |
| AVG Volume (30 Days) | ★ 1.6M | 123.5K |
| Earning Date | 05-05-2026 | 03-31-2026 |
| Dividend Yield | ★ 1.33% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $6,638,000,000.00 | N/A |
| Revenue This Year | $6.15 | $58.17 |
| Revenue Next Year | $5.95 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 7.36 | N/A |
| 52 Week Low | $10.44 | $14.78 |
| 52 Week High | $28.67 | $57.14 |
| Indicator | CC | NBTX |
|---|---|---|
| Relative Strength Index (RSI) | 42.19 | 38.87 |
| Support Level | $14.33 | $32.40 |
| Resistance Level | $16.37 | $34.66 |
| Average True Range (ATR) | 0.46 | 1.80 |
| MACD | 0.02 | -0.33 |
| Stochastic Oscillator | 31.40 | 22.69 |
The Chemours Co is a provider of chemicals. It delivers customized solutions with a wide range of industrial and specialty chemicals products for various markets including coatings, plastics, refrigeration, air conditioning, paints and coatings, plastics, transportation, semiconductor, and others. The company's operating segments include Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. It generates maximum revenue from the Titanium Technologies segment. The Titanium Technologies segment is a producer of TiO2 pigment, a premium white pigment used to deliver whiteness, brightness, opacity, durability, efficiency, and protection across a variety of applications. Geographically, the company derives a majority of its revenue from North America.
Nanobiotix SA is a late-stage clinical biotechnology company focused on re-inventing medicine by building new therapies atom by atom, developing widely applicable, first-in-class, physics-based nanotherapeutics to transform treatment outcomes and expand life for millions of patients. The objective of this physics-based approach is to allow nanoparticles to be combined with other drugs or therapeutic modalities and to integrate seamlessly into clinical practice without adding burden for the patient, healthcare provider, or healthcare system. It has three platforms Nanoradioenhancer platform: Nanoprimer platform: and Neurological disease platform. It has one segment, which is the research and development of product candidates that use proprietary nanotechnology to transform cancer treatment.